| 标题： | 中国高尿酸血症与痛风诊治指南（2024） |
| title： | 2023 Chinese Society of Endocrinology Guidelines for Management of Hyperuricemia and Gout |
| 版本： | 更新版 |
| version： | Updated |
| 分类： | 标准指南 |
| classification： | Standard guideline |
| 领域： | 综合 |
| field： | Comprehensive guideline |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 风湿科及内分泌科临床医生 |
| Guide users： | Rheumatology and Endocrinology Clinicians |
| 证据分级方法： | 本指南的整体设计与实施参照«世界卫生组织指南»及«临床诊疗指南的基本方法与程序»，指南评价工具采用 ARGEEII。指南分级标准采用GRADE分级系统。GRADE证据质量分级与定义：高级（A）非常确信真实效应值接近效应估计值；中级（B）对效应估计值有中等程度的信心:真实效应值有可能接近估计效应值,但仍存在两者大不相同的可能性；低级（C）对效应估计值的确信程度有限:真实效应值可能与效应估计值大不相同；极低级（D）对效应估计值几乎无信心:真实效应值很可能与效应，估计值大不相同 |
| Evidence grading method： | The overall design and implementation of this guideline refer to the World Health Organization Guidelines and the Basic Methods and Procedures of Clinical Diagnosis and Treatment Guidelines, and the guideline evaluation tool adopts ARGEEII. The grading standard of the guidelines adopts the GRADE grading system. GRADE evidence quality grading and definition: Advanced (A) is very confident that the true effect value is close to the estimated effect value; Intermediate (B) has moderate confidence in the estimated effect value: the true effect value may be close to the estimated effect value, but there is still a possibility of significant differences between the two; The lower level (C) has limited confidence in the estimated effect value: the true effect value may be significantly different from the estimated effect value; Very low level (D) has almost no confidence in the estimated effect value: the true effect value is likely to be significantly different from the estimated effect value |
| 制定单位： | 中华医学会内分泌学分会 |
| Formulating unit： | Chinese Society of Endocrinology |
| 注册时间： | 2024-04-21 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN563 |
| Registration number： | |
| 指南制订的目的： | 2019年中华医学会内分泌学分会发布了《中国高尿酸血症与痛风诊疗指南2019》。《高尿酸血症与痛风诊疗指南 2019》问题的产生最终形成了52个临床问题。采用微信调查问卷形式，发放问卷620份，覆盖27个省、自治区、直辖市和特别行政区，回收620份，有效率为100%。经过统计排序后，最终确定21个临床问题，整合为19个问题纳入该指南编写内容。 最终19个临床问题中1个因无证据未列入，余18个问题合并为12个，共形成了51条推荐意见。其中痛风急性发作期药物的选择 ，痛风合并高尿酸血症患者降尿酸药物的选择，合并慢性肾脏疾病患者降尿酸药物的选择和高尿酸血症和痛风伴发病相关药物的选择部分或全部推荐意见证据等级为C或更低，本次更新需关注。作为被临床医生关注的临床问题，存在于最初的19个问题列表中，但因为没有任何系统评价及指南的可参考，在 2019年指南生成中，最终未被纳入。此后5年，大量基础研究、临床研究及流行病学研究结果亟待推广，以提高广大临床医师对该组疾病的认识和规范诊治。同时，临床指南的制定方法也日趋科学、规范和国际化。因此，学会决定在2019版指南的基础上以规范的循证医学方法和流程更新中国内分泌专业HUA和痛风的诊治指南。 |
| Purpose of the guideline： | In 2019, the Endocrinology Branch of the Chinese Medical Association released the 2019 Chinese Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout. The emergence of the 2019 Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout ultimately led to 52 clinical issues. Using WeChat survey questionnaire format, 620 questionnaires were distributed, covering 27 provinces, autonomous regions, municipalities directly under the central government, and special administrative regions. 620 questionnaires were collected, with an effective rate of 100%. After statistical sorting, 21 clinical questions were finally identified and integrated into 19 questions to be included in the content of this guideline. Out of the final 19 clinical questions, 1 was not included due to lack of evidence, and the remaining 18 questions were merged into 12, resulting in a total of 51 recommended opinions. The selection of drugs for acute gout attacks, the selection of uric acid lowering drugs for gout patients with hyperuricemia, the selection of uric acid lowering drugs for patients with chronic kidney disease, and the selection of drugs related to hyperuricemia and gout comorbidities are partially or entirely recommended. The evidence level is C or lower, and attention should be paid to this update. As a clinical issue of concern to clinical doctors, it existed in the initial 19 question list, but was not included in the 2019 guideline generation due to the lack of any systematic evaluation and guidelines for reference. In the following five years, a large number of basic research, clinical research, and epidemiological research results urgently need to be promoted to improve the understanding and standardized diagnosis and treatment of this group of diseases among clinical physicians. At the same time, the methods for developing clinical guidelines are becoming increasingly scientific, standardized, and internationalized. Therefore, the society has decided to update the diagnosis and treatment guidelines for HUA and gout in the Chinese endocrinology profession with standardized evidence-based medicine methods and processes based on the 2019 guidelines. |
最新注册
